Document is current

Article History

Received: 29 March 2022

Accepted: 23 August 2022

First Online: 21 September 2022

Competing interests

: J.J.A, A.G., and K.B. are employees of EIP Pharma, the sponsor of the clinical study. J.J.A. is also founder of and has stock ownership in EIP Pharma. U.A.G. receives compensation as a scientific consultant to EIP Pharma. S.N.G. has served on Advisory Boards of Jannsen, Acadia, and Sanofi, has received consulting fees from EIP Pharma, and has received funding from the NIH, the DOD CDMRP, the Michael J. Fox Foundation, the FFFPRI, and the Lewy Body Dementia Association. N.D.P. is CEO and co-owner of Brain Research Center. P.M. is a full-time employee at Cogstate Ltd. J.E.H. reports receipt of personal fees in the past 2 years from Actinogen, AlzeCure, Aptinyx, Astra Zeneca, Athira Therapeutics, Axon Neuroscience, Axovant, Bial Biotech, Biogen Idec, BlackThornRx, Boehringer Ingelheim, Brands2life, Cerecin, Cognito, Cognition Therapeutics, Compass Pathways, Corlieve, Curasen, EIP Pharma, Eisai, G4X Discovery, GfHEU, Heptares, Ki Elements, Lundbeck, Lysosome Therapeutics, MyCognition, Neurocentria, Neurocog, Neurodyn Inc, Neurotrack, the NHS, Novartis, Novo Nordisk, Nutricia, Probiodrug, Prothena, Recognify, Regeneron, reMYND, Rodin Therapeutics, Samumed, Sanofi, Signant, Syndesi Therapeutics, Takeda, Vivoryon Therapeutics and Winterlight Labs. In addition, he holds stock options in Neurotrack Inc. and is a joint holder of patents with My Cognition Ltd. C.E.T. has a collaboration contracts with ADx Neurosciences, Quanterix and Eli Lilly; performed contract research or received grants from AC-Immune, Axon Neurosciences, Bioconnect, Bioorchestra, Brainstorm Therapeutics, Celgene, EIP Pharma, Eisai, Grifols, Novo Nordisk, PeopleBio, Roche, Toyama, and Vivoryon; and has had speaker contracts for Roche, Grifols, and Novo Nordisk. P.S. has received consultancy fees (paid to the institution) from AC Immune, Brainstorm Cell, EIP Pharma, ImmunoBrain Checkpoint, Genentech, Novartis, Novo Nordisk. P.S. is also principal investigator of studies with AC Immune, FUJI-film/Toyama, UCB, and Vivoryon; and is an employee of EQT Life Sciences (formerly LSP). The remaining authors declare no competing interests.